"Xing Mang" Series Tumor Genomic Testing Products Launched by Nebula Genomics in Collaboration with Illumina

Recently, Nebula Genomics announced a collaboration with Illumina, the global leader in gene sequencing and microarray technologies, in the field of precision medicine for solid tumors. This strategic partnership aims to further expand the clinical application of next-generation sequencing (NGS) technology in oncology testing, thereby promoting the standardized development of precision diagnosis and treatment for solid tumors in China.

Nebula GenomicsIntroduction of the Illumina TruSight™ Oncology 500 (TSO 500) pan-solid tumor gene detection kit, combined with our own years of accumulated R&D achievements, developing for the Chinese genetic testing market solutions that better meet the needs of Chinese cancer patients“Starlight” Series Genetic Testing Products。

““Starlight” Series Genetic Testing ProductsCovers comprehensive pan-cancer pharmacogenomic testing (Xingyuankang) and precision pharmacogenomic testing for various high-incidence cancers,Advanced and reliable technology, comprehensive content coverage, supplemented by authoritative guidance from high-quality evidence sources, matching patients with targeted therapies, immunosuppressants, and chemotherapy regimens helps improve clinical outcomes; meanwhile, it unlocks eligibility for clinical trials based on molecular target matching, thereby identifying potential therapeutic opportunities.To ensure optimal patient benefit.

After more than two years of rigorous research, development, and validation, it has been confirmed that through“Starburst” SeriesTumor Gene TestingIdentification of biomarkers for drug accessibility significantly contributes to optimizing treatment regimens for patients with solid tumors, a remarkable achievement stemming from two key product features—Reliability & Comprehensiveness.

1. Analytical specificity ≥99.9995%, analytical sensitivity >95%, robust detection performance ensures high sensitivity and high specificity, significantly reducing false negatives and false positives.

2. Unique Molecular Identifier (UMI)Technically label original molecular fragments to ensure accurate detection of ultra-low frequency variants, with key hotspot variants as low as0.2%。

3. Low Sample SizeStable detection is still achievable: The variant allele frequency in 20–40 ng DNA samples, the number of mutations per megabase (Mb), and the percentage of microsatellite instability loci all demonstrate high consistency.

4. FeasibleEffective IdentificationAny steps during sample collection, library preparation, etc.Cross-contamination。

5. Reliable Biomarkers for Immunotherapy:TMBThe test results are highly consistent with those of whole-exome sequencing (the gold standard);MSIThe concordance rate between the test data and the Promega MSI assay (an FDA-approved kit) is as high as 98%.

1. Comprehensive Biomarkers:Xingyuankang provides comprehensive coverage of biomarkers for sensitivity or resistance to targeted therapies; FDA-approved biomarkers for immunotherapy (TMB, MSI, MMR); biomarkers associated with positive or negative responses to immunotherapy and immune hyperprogression; biomarkers related to the efficacy and adverse effects of chemotherapy; newly identified key biomarkers; and genes involved in signaling pathways associated with tumorigenesis and progression.

2. Comprehensive Report Interpretation:It covers medications approved by the FDA and NMPA, drugs recommended by authoritative domestic and international guidelines and expert consensuses such as the NCCN and CSCO guidelines, investigational drugs in clinical trials both domestically and internationally, and medications reported in cutting-edge presentations at ASCO/ESMO and in high-credibility literature. All content has been manually reviewed and proofread to ensure accuracy.

3. Comprehensive coverage of cancer types:Applicable to 16 common solid tumors, supporting both tumor tissue and blood cfDNA samples.

4. Panoramic Variant Analysis (GCP): With a single sample and a single test, all types of genetic variants associated with specific solid tumors can be analyzed, including SNVs, insertions and deletions (Indels), fusions, and CNVs.

Select “Starburst” to perform a singleReliable Testing, providingComprehensive Analysis, for selecting patients with target mutationsBetter Treatment Options!